BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu YP, Zheng CC, Huang YN, He ML, Xu WW, Li B. Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. MedComm (2020) 2021;2:315-40. [PMID: 34766149 DOI: 10.1002/mco2.55] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Benesch MGK, O’brien SBL. Epidemiology of Undifferentiated Carcinomas. Cancers 2022;14:5819. [DOI: 10.3390/cancers14235819] [Reference Citation Analysis]
2 Oliveira MC, Verswyvel H, Smits E, Cordeiro RM, Bogaerts A, Lin A. The pro- and anti-tumoral properties of gap junctions in cancer and their role in therapeutic strategies. Redox Biol 2022;57:102503. [PMID: 36228438 DOI: 10.1016/j.redox.2022.102503] [Reference Citation Analysis]
3 Ni B, Song X, Shi B, Wang J, Sun Q, Wang X, Xu M, Cao L, Zhu G, Li J. Research progress of ginseng in the treatment of gastrointestinal cancers. Front Pharmacol 2022;13:1036498. [DOI: 10.3389/fphar.2022.1036498] [Reference Citation Analysis]
4 Sun XY, Li HZ, Xie DF, Gao SS, Huang X, Guan H, Bai CJ, Zhou PK. LPAR5 confers radioresistance to cancer cells associated with EMT activation via the ERK/Snail pathway. J Transl Med 2022;20:456. [PMID: 36199069 DOI: 10.1186/s12967-022-03673-4] [Reference Citation Analysis]
5 Huang YJ, Huang MY, Cheng TL, Kuo SH, Ke CC, Chen YT, Hsieh YC, Wang JY, Cheng CM, Chuang CH. ERCC1 Overexpression Increases Radioresistance in Colorectal Cancer Cells. Cancers (Basel) 2022;14:4798. [PMID: 36230725 DOI: 10.3390/cancers14194798] [Reference Citation Analysis]
6 Dal Bello S, Valdemarin F, Martinuzzi D, Filippi F, Gigli GL, Valente M. Ketogenic Diet in the Treatment of Gliomas and Glioblastomas. Nutrients 2022;14:3851. [PMID: 36145228 DOI: 10.3390/nu14183851] [Reference Citation Analysis]
7 Komorowska D, Radzik T, Kalenik S, Rodacka A. Natural Radiosensitizers in Radiotherapy: Cancer Treatment by Combining Ionizing Radiation with Resveratrol. IJMS 2022;23:10627. [DOI: 10.3390/ijms231810627] [Reference Citation Analysis]
8 Hashemi M, Moosavi MS, Abed HM, Dehghani M, Aalipour M, Heydari EA, Behroozaghdam M, Entezari M, Salimimoghadam S, Gunduz ES, Taheriazam A, Mirzaei S, Samarghandian S. Long non-coding RNA (lncRNA) H19 in human cancer: From proliferation and metastasis to therapy. Pharmacol Res 2022;184:106418. [PMID: 36038043 DOI: 10.1016/j.phrs.2022.106418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Sajeev A, Hegde M, Daimary UD, Kumar A, Girisa S, Sethi G, Kunnumakkara AB. Modulation of diverse oncogenic signaling pathways by oroxylin A: An important strategy for both cancer prevention and treatment. Phytomedicine 2022. [DOI: 10.1016/j.phymed.2022.154369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Peña-flores JA, Bermúdez M, Ramos-payán R, Villegas-mercado CE, Soto-barreras U, Muela-campos D, Álvarez-ramírez A, Pérez-aguirre B, Larrinua-pacheco AD, López-camarillo C, López-gutiérrez JA, Garnica-palazuelos J, Estrada-macías ME, Cota-quintero JL, Barraza-gómez AA. Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma. Front Oncol 2022;12:965628. [DOI: 10.3389/fonc.2022.965628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Saleh T, As Sobeai HM, Alhoshani A, Alhazzani K, Almutairi MM, Alotaibi M. Effect of Autophagy Inhibitors on Radiosensitivity in DNA Repair-Proficient and -Deficient Glioma Cells. Medicina 2022;58:889. [DOI: 10.3390/medicina58070889] [Reference Citation Analysis]
12 Ke Y, Liao CG, Zhao ZQ, Li XM, Lin RJ, Yang L, Zhang HL, Kong LM. Combining a CDK4/6 Inhibitor With Pemetrexed Inhibits Cell Proliferation and Metastasis in Human Lung Adenocarcinoma. Front Oncol 2022;12:880153. [PMID: 35686110 DOI: 10.3389/fonc.2022.880153] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Gupta K, Jones JC, Farias VA, Mackeyev Y, Singh PK, Quiñones-Hinojosa A, Krishnan S. Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma. Front Oncol 2022;12:840241. [PMID: 35664781 DOI: 10.3389/fonc.2022.840241] [Reference Citation Analysis]
14 Mousa AM, Soliman KEA, Alhumaydhi FA, Almatroudi A, Allemailem KS, Alsahli MA, Alrumaihi F, Aljasir M, Alwashmi ASS, Ahmed AA, Khan A, Al-Regaiey KA, AlSuhaymi N, Alsugoor MH, Aljarbou WA, Elsayed AM. Could allicin alleviate trastuzumab-induced cardiotoxicity in a rat model through antioxidant, anti-inflammatory, and antihyperlipidemic properties? Life Sci 2022;302:120656. [PMID: 35605695 DOI: 10.1016/j.lfs.2022.120656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Mesci A, Wong RK. Current and future strategies for radiation therapy in gastric cancer. J Surg Oncol 2022;125:1161-75. [PMID: 35481918 DOI: 10.1002/jso.26880] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Wang J, Liu J, Wang J, Wang S, Li F, Li R, Liu P, Li M, Wang C. Identification of proteomic markers for prediction of the response to 5-Fluorouracil based neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Cancer Cell Int 2022;22:117. [PMID: 35292026 DOI: 10.1186/s12935-022-02530-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 An J, Peng C, Xie X, Peng F. New Advances in Targeted Therapy of HER2-Negative Breast Cancer. Front Oncol 2022;12:828438. [DOI: 10.3389/fonc.2022.828438] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Akter S, Rahman MA, Hasan MN, Akhter H, Noor P, Islam R, Shin Y, Rahman MH, Gazi MS, Huda MN, Nam NM, Chung J, Han S, Kim B, Kang I, Ha J, Choe W, Choi TG, Kim SS. Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements. Cells 2022;11:650. [DOI: 10.3390/cells11040650] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
19 Diniz F, Coelho P, Duarte HO, Sarmento B, Reis CA, Gomes J. Glycans as Targets for Drug Delivery in Cancer. Cancers 2022;14:911. [DOI: 10.3390/cancers14040911] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
20 Fu Y, Ci H, Du W, Dong Q, Jia H. CHRNA5 Contributes to Hepatocellular Carcinoma Progression by Regulating YAP Activity. Pharmaceutics 2022;14:275. [DOI: 10.3390/pharmaceutics14020275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Gueble SE, Bindra RS. Oncometabolites as Regulators of DNA Damage Response and Repair. Semin Radiat Oncol 2022;32:82-94. [PMID: 34861999 DOI: 10.1016/j.semradonc.2021.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Liu YP, Zheng CC, Huang YN, He ML, Xu WW, Li B. Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. MedComm (2020) 2021;2:315-40. [PMID: 34766149 DOI: 10.1002/mco2.55] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 17.0] [Reference Citation Analysis]